Clinical responses to TLR9 for head and neck squamous cell carcinoma occurred in both PD-L1 high and low tumors,104 suggesting a benefit for patients who do not respond to ICIs due to low PD-L1 levels. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.